by Arlene Weintraub | Aug 27, 2020 11:47am
https://www.fiercepharma.com/pharma/pfizer-could-score-fast-covid-vaccine-approval-as-fda-s-hahn-promises-october-review-analyst
[-chart]qtxasset.com/styles/breakpoint_xl_880px_w/s3/fiercepharma/1598536932/vaccinecreditGuschenkovaiStockGettyImagesPlusGettyImages_0.jpg/vaccinecreditGuschenkovaiStockGettyImagesPlusGettyImages_0.jpg?6a6Capdic99L2BG2UpABY09up_jVF_eq&itok=xka2ezE4[/chart]
Pfizer should complete enrollment of its 30,000-person trial of its COVID vaccine next month and have initial data by mid-September, Mizuho predicted. (Guschenkova/iStockGettyImages)
FDA Commissioner Stephen Hahn, M.D., was fresh off a controversy over the emergency use authorization for convalescent plasma to treat COVID-19 when he made waves again, this time promising on Twitter that the agency would review coronavirus vaccines before the November election.
And Pfizer executives appear to be in sync with that timeline, as they race to complete a phase 3 trial of their vaccine candidate.
Nicholas Kitchin, M.D., a senior director in Pfizer's vaccine R&D group, told the Centers for Disease Control on Wednesday that the clinical trial of the company’s BioNTech-partnered COVID vaccine, BNT162b2, is more than 50% enrolled.
The news followed several public comments from Pfizer’s CEO Albert Bourla regarding the company’s plan to seek FDA approval of the vaccine in October.
FIERCE WEBINAR
Leveraging Innovative Technologies, Best Practices and Strategies to Accelerate Biologics Development and Commercialization
Learn practical implementation of innovative technologies and solutions such as multi-attribute method, modernized cell line development workflow using high-yield cell lines and automated systems, next generation purification resins.
The webinar will also showcase best practices and strategies such as phase appropriate quality systems, and integrated drug substance – drug product solutions that leverage standardized technology platforms.
SAVE YOUR SPOT
Hahn took to Twitter saying the agency’s reviewers are “encouraged by the rapid rate of enrollment” in clinical trials of COVID-19 vaccines.
Hahn also noted that the vaccine advisory committee would meet on October 22. The comments were noteworthy, given that the FDA’s website does not list that committee meeting on its calendar.
Mizuho Securities analyst Vamil Divan figures that vaccine timeline can only benefit Pfizer.
If the company is already halfway to its goal of recruiting 30,000 patients in the mRNA vaccine trial, he figured, the company should “reach full enrollment by end of next month,” Divan wrote in a note sent to investors Thursday.
That means the first dataset should be released in mid-September, potentially at an investor event the company has scheduled for that time.
All of the data from the trial could be ready by mid-October, Divan added, just in time for the FDA committee meeting.
“While difficult to predict, this does set the stage for potential … review and FDA Emergency Use Authorization in that same time period,” he wrote.
Pfizer did not immediately respond to a request for comment.
RELATED: Moderna outlook too rosy amid multiple potential COVID-19 vaccines: analyst
Divan estimates that Pfizer’s COVID vaccine could launch late this year and reach peak sales of about $1.7 billion in 2021.
Sales will fall to $850 million in 2023, after which the vaccine will bring in annual sales between $500 million and $600 million, assuming “a flu-like scenario with annual vaccinations,” he predicted.
Pfizer is facing competition, notably from Moderna, which is also working on an mRNA vaccine to prevent COVID-19. But SVB Leerink analysts pointed out in a note earlier this week that Pfizer has some key advantages:
Its vaccine is the only candidate to have produced confirmed responses in CD4+ and CD8+ T cells in human trials—a sign of strong immune protection—the analysts said.
And Pfizer has a strong infrastructure and commercial expertise that the much younger Moderna lacks, SVB Leerink analysts added.
There's also AstraZeneca and its Oxford University-partnered shot.
Earlier this week, the Financial Times reported that the Trump administration was weighing a potential OK for that vaccine before the election.
AstraZeneca said Tuesday it had not discussed an emergency authorization with U.S. officials.
The shot is in phase 2/3 testing in the U.K., Brazil and South Africa, and the company doesn’t “anticipate efficacy results until later this year," a spokeswoman said via email.
RELATED: Johnson & Johnson gears up for 60,000-person COVID-19 vaccine trial, the industry's biggest yet
Several other COVID vaccine contenders will also be vying for market share, some of which have developed their candidates using technology that’s already proven, unlike mRNA.
They include Johnson & Johnson, which plans to enroll 60,000 people in a trial of its vaccine, Ad26.COV2.S.
J&J developed the vaccine using the same technology behind an Ebola vaccine that’s been given to more than 60,000 people.
SVB Leerink tempered its predictions for Moderna after speaking with three specialists who suggested that protein subunit vaccines might be more attractive than the mRNA candidates.
Sanofi and GlaxoSmithKline are working on a protein subunit vaccine, as is Novavax, which is gearing up for its phase 3 trial now.
The FDA's Hahn, who took some heat for incorrectly stating that convalescent plasma is associated with a 35% improvement in survival in COVID-19 patients, was quick to tweet that the October 22 review of vaccine candidates would hinge on "good scientific data."
But that didn't stop some critics from pointing out that said meeting would be happening just days before the presidential election.
As for Pfizer, it continues to rack up supply deals for its vaccine. In late July,
it locked down a $1.95 billion order from the U.S. government for 100 million doses. It also has supply deals with the U.K. and Japan.
Recent BNTX News
- Anglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More News • IH Market News • 04/26/2024 11:48:07 AM
- Coca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More News • IH Market News • 04/24/2024 11:28:02 AM
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024 • GlobeNewswire Inc. • 04/22/2024 10:45:00 AM
- Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer • GlobeNewswire Inc. • 04/07/2024 06:00:00 PM
- Apple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market Updates • IH Market News • 03/21/2024 11:17:26 AM
- U.S. Index Futures Trade Sideways Amid Anticipation of Fed’s Policy Update; Oil Prices Dip • IH Market News • 03/20/2024 11:17:32 AM
- BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update • GlobeNewswire Inc. • 03/20/2024 10:15:00 AM
- BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer • GlobeNewswire Inc. • 03/20/2024 10:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/11/2024 01:04:00 PM
- BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024 • GlobeNewswire Inc. • 03/11/2024 11:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 12, 2024 in BioNTech Lawsuit - BNTX • PR Newswire (US) • 03/11/2024 10:25:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/07/2024 01:41:50 PM
- BioNTech Announces Planned Retirement of Sean Marett • GlobeNewswire Inc. • 03/07/2024 11:45:00 AM
- BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024 • GlobeNewswire Inc. • 03/06/2024 11:45:00 AM
- The Gross Law Firm Reminds BioNTech SE Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 12, 2024 - BNTX • PR Newswire (US) • 03/05/2024 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/28/2024 11:26:07 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/26/2024 10:45:00 AM
- BioNTech SE Sued for Securities Law Violations - Contact The Gross Law Firm Before March 12, 2024 to Discuss Your Rights - BNTX • PR Newswire (US) • 02/22/2024 10:45:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/15/2024 09:10:24 PM
- Shareholders that lost money on BioNTech SE(BNTX) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 02/15/2024 10:00:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 12:26:25 PM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of BioNTech SE(BNTX) Shareholders • PR Newswire (US) • 02/09/2024 10:45:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/08/2024 11:08:22 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs • GlobeNewswire Inc. • 02/08/2024 10:45:00 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM